La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

'Sandoz will be the Leading Biosimilar Drug Company in 2012, With Revenue Of $308 Million' Predicts New Visiongain Report

3 pages
'Sandoz will be the Leading Biosimilar Drug Company in 2012, With Revenue Of $308 Million' Predicts New Visiongain Report PR Newswire LONDON, October 4, 2012 LONDON, October 4, 2012 /PRNewswire/ -- A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308m in revenue. Combined revenue for the top three companies in that market will grow with a CAGR of close to 25% between 2011 and 2016. Those findings, and others, appear in Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022, published in October 2012. Visiongain's analysis indicates that, in 2011, the top ten biosimilar drug manufacturers accounted for 54.8% of that market. Global generics manufacturers occupied three of the top four places in the ranking. Leading manufacturers based in India, China and South Korea were also among the top ten biosimilar manufacturers. All companies among the top 25 will experience revenue growth in the coming 10 years, although most will have market share fall. Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Many of the top 25 biosimilar manufacturers have an established base in the market, having marketed products for the past five to ten years. However, many will see their position challenged in the coming decade.
Voir plus Voir moins

'Sandoz will be the Leading Biosimilar Drug Company in 2012, With Revenue Of $308 Million' Predicts New Visiongain Report

PR Newswire

LONDON, October 4, 2012 /PRNewswire/ --

A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308m in revenue. Combined revenue for the top three companies in that market will grow with a CAGR of close to 25% between 2011 and 2016. Those findings, and others, appear in Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022, published in October 2012.

Visiongain's analysis indicates that, in 2011, the top ten biosimilar drug manufacturers accounted for 54.8% of that market. Global generics manufacturers occupied three of the top four places in the ranking. Leading manufacturers based in India, China and South Korea were also among the top ten biosimilar manufacturers. All companies among the top 25 will experience revenue growth in the coming 10 years, although most will have market share fall.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Many of the top 25 biosimilar manufacturers have an established base in the market, having marketed products for the past five to ten years. However, many will see their position challenged in the coming decade. Rapid growth forecast for the biosimilars market has made it an attractive prospect and many new companies are looking to enter.

"To retain market share, current leaders will launch new biosimilars in the next few years, focusing particularly on monoclonal antibodies (mAbs). Licensing deals will extend the pipelines of established players and new market entrants. Eight of Hospira's eleven pipeline biosimilars are from its licensing agreement with Celltrion, for example. More deals are expected in this sector in the near future as companies look for a foothold in this fast-growing market."

Visiongain's study forecasts biosimilar revenues to 2022 for eight of the leading companies. Two established market players will achieve biosimilar revenue over $2bn by 2022. Dr. Reddy's will experience the fastest revenue growth in the period, with a CAGR of over 30%. The launch of seven new biosimilars between 2012 and 2018 will stimulate this growth.

Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 shows analyses of the leading companies in this market. The report provides discussion of portfolio and pipeline products, as well as SWOT analysis, for each. It adds to visiongain's range of Pharma Leader Series reports, assessing the prospects of leading companies in important pharmaceutical sectors. Visiongain is a business information provider based in London, UK.


For further information concerning the Visiongain's Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 report please visit http://www.visiongain.com/Report/906/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2012-2022

Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44-(0)20-7336-6100

Companies listed in this report include:
3SBio (Shenyang Sunshine Pharmaceutical)
Abbott Laboratories
Aché
Actavis (part of Watson)
Affitech
Amega Biotech
Amgen
Amicus Therapeutics
Anglo Gulf (part of MJ Group)
Apotex
Aprogen
ASKA Pharmaceutical
AstraZeneca
Avesthagen
AxiCorp
AzkoNobel
Baxter International
Bayer
Beijing Four Rings Bio-pharmaceutical
Beijing SL Pharmaceutical
Bigpearl Trading (part of Pharmstandard)
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biogen Idec
BioGeneriX (part of Teva)
BioMab
Biomed (part of Pharmstandard)
Bionovis
Biopartners (part of Bioton)
Biopharmaceuticals and Herbal Medicines Bureau [South Korea]
Biosidus (part of Sidus Pharmaceutical Group)
Bioton
Biovel Life Sciences (part of Ranbaxy)
Blau Farmacêutica
Boehringer Ingelheim
Bristol-Myers Squibb
cell pharm (part of Stada)
Celltrion
Central Drugs Standard Control Organization (CDSCO) [India]
Chemo Group
China National Pharmaceutical Group (Sinopharm)
CinnaGen
Cipla
CJ Corporation
Clinigene International (part of Biocon)
CoGenesys (part of Teva)
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Committee for Medicinal Products for Human Use (CHMP) [EU]
CT Arzneimittel (part of Teva)
CureTech (part of Teva)
Daiichi Sankyo
Dainippon Sumitomo Pharma
DaVita
Department of Biotechnology (DBT) [India]
Diapin Therapeutics
DM Bio
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Eden Biodesign (part of Watson)
Egis Pharmaceuticals
Eli Lilly
Emcure Pharmaceuticals
EMS
Epitomics
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Finox
Food and Drug Administration (FDA), [US]
Fosun International
Fresenius Medical Care
Fuji Pharma
Fujifilm
Fundação Ezequiel Dias (Funed) [Brazil]
Gan & Lee Pharmaceutical
Gedeon Richter
Genentech (part of Roche)
GeneScience Pharmaceuticals
Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals)
Genzyme (part of Sanofi)
German Remedies (part of Zydus Cadila)
Germonta Holdings (part of Bioton)
Green Cross Corporation
GSK
Hangzhou Jiuyuan Gene Engineering
Hanwha Chemical
Haselmeier
Hefei-SciGen-Bioton Biopharmaceutical Company
Hemofarm (part of Stada)
Hexal (part of Novartis)
Hikma Pharmaceuticals
Hospira
Hospira Japan (part of Hospira)
Hualida Biotech
Human Genome Sciences (part of GSK)
Hypermarcas
IATRICa
Insmed
Intas Biopharmaceuticals (part of Intas Pharmaceuticals)
Intas Pharmaceuticals
International Biotech Center (IBC) Generium
Isotechnika Pharma
Isu Abxis
Itero Biopharmaceuticals
JCR Pharmaceuticals
Johnson & Johnson (J&J)
Kissei Pharmaceutical
Korea Food and Drug Administration (KFDA)
Kwizda Pharma
Kyowa Hakko Kirin
Laboratórios Biosintética (part of Aché)
Landsteiner Scientific
Lekko (part of Pharmstandard)
LG
LG Chem Investment (part of LG)
LG Life Sciences
Lonza
Lupin Pharmaceuticals
MabPharm
Marvel Life Sciences (part of MJ Group)
Masterlek (part of Pharmstandard)
Medice Arzneimittel Pütter
MedImmune (part of AstraZeneca)
Meiji Seika Pharma
Merck & Co.
Merck KGaA
Mindar Holdings (part of Bioton)
Ministry of Health [Brazil]
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Ministry of Science and Technology [India]
MJ Biopharm (part of MJ Group)
MJ Bioton Life Sciences
MJ Group
Mochida Pharmaceutical
Mylan
NeuClone
Nichi-Iko Pharmaceutical
Nippon Kayaku
Nipro Pharma
Nobel Ilac
Norbitec
Nordmark Arzneimittel
Novartis
Novo Nordisk
Organon (part of Merck & Co.)
Owen Mumford
Parexel International
Pfenex
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Pharmapark (part of Pharmstandard)
Pharmstandard
Pharmstandard-Biolek (part of Pharmstandard)
Pliva (part of Teva)
Polpharma
Polpharma Biologics (part of Polpharma)
Probiomed
Prolong Pharmaceuticals
Proquifin
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
ratiopharm (part of Teva)
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Group
Reliance Life Sciences (part of Reliance Group)
Rentschler Biotechnologie
Roche
Royal DSM
Safety Syringes
Samsung
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
sanofi-aventis Nichi-Iko
Savient Pharmaceuticals (part of Ferring)
Schering-Plough (part of Merck & Co.)
Schnell Biopharmaceuticals
SciGen
Shandong Kexing Bioproducts
Shanghai Celgen Bio-Pharmaceutical
Shanghai Chemo Wanbang Biopharma
Shanghai CP Goujian Pharmaceutical
Shanghai Fosun Pharmaceutical
Shanghai Henlius Biotech
Shantha Biotechnics (part of Sanofi)
Sicor Biotech (part of Teva)
Sidus Pharmaceutical Group
Silanes
Stada Arzneimittel
State Food and Drug Administration (SFDA) [China]
State's Employees´ Social Security and Social Services Institute (ISSSTE) [Mexico]
Sundiro Pharma
Syngene (part of Biocon)
Teva Pharmaceutical Industries
Teva-Kowa Pharma (part of Teva)
The United Laboratories
Therapeutic Goods Administration (TGA) [Australia]
TL Biopharmaceutical
Tonghua Dongbao
União Química
University of Michigan
Wanbang Biopharmaceuticals (part of Shanghai Fosun Pharmaceuticals)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Xiamen Amoytop Biotech
Ypsomed
Zao Indar
Zenotech Laboratories
Zuventus Healthcare (part of Emcure Pharmaceuticals)
Zydus Cadila 

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.


Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin